Trial Profile
A Real-World Study Investigating Maintenance Rituximab after First Line Induction Therapy in Patients with Follicular Lymphoma treated at the Veterans Health Administration (VHA)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 31 Jan 2019
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Bendamustine; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
- Indications Follicular lymphoma
- Focus Therapeutic Use
- 04 Dec 2018 Results assessing factors associated with overall survival, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
- 27 Dec 2017 New trial record
- 12 Dec 2017 According to results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology, the end date of study observation period is 31 Dec 2016.